Acro Biomedical Co., Ltd. (ACBM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 201.11 Thousand USD | 71.35% |
| 2021 | 117.37 Thousand USD | -62.4% |
| 2020 | 312.18 Thousand USD | 133.17% |
| 2019 | 133.88 Thousand USD | -44.37% |
| 2018 | 240.67 Thousand USD | 550.84% |
| 2017 | 36.97 Thousand USD | 113.43% |
| 2016 | 17.32 Thousand USD | 2000.12% |
| 2015 | 825.00 USD | 0.0% |
| 2014 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 199.49 Thousand USD | -18.92% |
| 2023 Q1 | 246.03 Thousand USD | 22.33% |
| 2022 Q2 | 94.44 Thousand USD | 10.62% |
| 2022 FY | 201.11 Thousand USD | 71.35% |
| 2022 Q1 | 85.37 Thousand USD | -27.26% |
| 2022 Q4 | 201.11 Thousand USD | 32.76% |
| 2022 Q3 | 151.48 Thousand USD | 60.4% |
| 2021 Q2 | 60.15 Thousand USD | -80.59% |
| 2021 Q4 | 117.37 Thousand USD | 90.5% |
| 2021 Q3 | 61.61 Thousand USD | 2.41% |
| 2021 Q1 | 309.99 Thousand USD | -0.7% |
| 2021 FY | 117.37 Thousand USD | -62.4% |
| 2020 Q4 | 312.18 Thousand USD | 28.14% |
| 2020 FY | 312.18 Thousand USD | 133.17% |
| 2020 Q3 | 243.62 Thousand USD | 34.4% |
| 2020 Q2 | 181.26 Thousand USD | 29.8% |
| 2020 Q1 | 139.65 Thousand USD | 4.31% |
| 2019 Q4 | 133.88 Thousand USD | -31.62% |
| 2019 Q1 | 141.25 Thousand USD | 37.04% |
| 2019 Q3 | 195.79 Thousand USD | 47.11% |
| 2019 FY | 133.88 Thousand USD | -44.37% |
| 2019 Q2 | 133.09 Thousand USD | -5.78% |
| 2018 FY | 240.67 Thousand USD | 550.84% |
| 2018 Q4 | 103.07 Thousand USD | -57.17% |
| 2018 Q3 | 240.67 Thousand USD | 3.39% |
| 2018 Q2 | 232.78 Thousand USD | 12.51% |
| 2018 Q1 | 206.91 Thousand USD | 19.62% |
| 2017 Q2 | 30.66 Thousand USD | 67.77% |
| 2017 FY | 36.97 Thousand USD | 113.43% |
| 2017 Q4 | 172.97 Thousand USD | 367.77% |
| 2017 Q3 | 36.97 Thousand USD | 20.59% |
| 2017 Q1 | 18.27 Thousand USD | -25.69% |
| 2016 FY | 17.32 Thousand USD | 2000.12% |
| 2016 Q2 | 11 Thousand USD | 235.27% |
| 2016 Q1 | 3283.00 USD | 99.21% |
| 2016 Q3 | 17.32 Thousand USD | 57.41% |
| 2016 Q4 | 24.59 Thousand USD | 41.97% |
| 2015 FY | 825.00 USD | 0.0% |
| 2015 Q3 | 825.00 USD | 13650.0% |
| 2015 Q2 | 6.00 USD | 0.0% |
| 2015 Q4 | 1648.00 USD | 99.76% |
| 2014 FY | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -633.117% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 97.875% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.722% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 75.134% |
| Rebus Holdings, Inc. | 5.24 Million USD | 96.163% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 99.659% |
| Qrons Inc. | 1.48 Million USD | 86.491% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | 83.599% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.732% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -349.964% |
| Skye Bioscience, Inc. | 14.07 Million USD | 98.571% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 99.623% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 97.901% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 52.293% |
| SQZ Biotechnologies Company | 50.03 Million USD | 99.598% |
| Intellipharmaceutics International Inc. | 12 Million USD | 98.325% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 94.778% |
| Mesoblast Limited | 188.44 Million USD | 99.893% |
| Marizyme, Inc. | 26.67 Million USD | 99.246% |
| Genus plc | 485 Million USD | 99.959% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 96.558% |
| Pharming Group N.V. | 244.07 Million USD | 99.918% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 89.995% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 92.008% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 94.707% |
| ContraFect Corporation | 32.53 Million USD | 99.382% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 89.849% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 94.746% |
| IMV Inc. | 37.93 Million USD | 99.47% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 98.292% |
| MultiCell Technologies, Inc. | 1617.67 USD | -12332.449% |
| ONE Bio Corp. | 27.49 Million USD | 99.269% |
| Accustem Sciences Inc. | 1.07 Million USD | 81.365% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.74% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 90.491% |
| Q BioMed Inc. | 8.13 Million USD | 97.527% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.758% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 96.092% |
| Biomind Labs Inc. | 1.49 Million USD | 86.58% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.831% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 97.776% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 98.907% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 85.974% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -41.536% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 96.5% |
| GB Sciences, Inc. | 5.41 Million USD | 96.288% |
| Alpha Cognition Inc. | 7.16 Million USD | 97.193% |
| HST Global, Inc. | 593.59 Thousand USD | 66.119% |
| CSL Limited | 18.62 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 84.028% |
| Halberd Corporation | 728.71 Thousand USD | 72.401% |
| Enzolytics Inc. | 365.26 Million USD | 99.945% |
| Agentix Corp. | 2.51 Million USD | 91.989% |
| Resverlogix Corp. | 67.39 Million USD | 99.702% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 76.021% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.955% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 88.266% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 99.187% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 98.31% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 94.513% |
| AVAX Technologies, Inc. | 3.99 Million USD | 94.964% |
| Zenith Capital Corp. | 27.56 Thousand USD | -629.501% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.985% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | 15.729% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 94.614% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 70.46% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 92.583% |
| Kadimastem Ltd | 3.5 Million USD | 94.262% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -200.492% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 99.6% |
| BioStem Technologies, Inc. | 15.9 Million USD | 98.735% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 56.721% |
| LadRx Corporation | 2.2 Million USD | 90.861% |
| Cell Source, Inc. | 15.8 Million USD | 98.728% |
| Regen BioPharma, Inc. | 5.45 Million USD | 96.315% |
| Regen BioPharma, Inc. | 5.45 Million USD | 96.315% |
| NovAccess Global Inc. | 7.86 Million USD | 97.442% |
| Affymax, Inc. | 8.87 Million USD | 97.733% |
| Itoco Inc. | 1.65 Million USD | 87.834% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 90.197% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 96.675% |
| Mobile Lads Corp. | 1.31 Million USD | 84.689% |
| CytoDyn Inc. | 127.89 Million USD | 99.843% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -381.15% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 87.16% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 98.179% |
| SYBLEU INC | 681.41 Thousand USD | 70.485% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 96.704% |
| International Stem Cell Corporation | 5.27 Million USD | 96.189% |
| Bioxytran, Inc. | 3.24 Million USD | 93.811% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 67.863% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 95.644% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 99.509% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 99.097% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 90.07% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 96.329% |
| Neutra Corp. | 973.52 Thousand USD | 79.342% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 99.307% |
| PureTech Health plc | 125.58 Million USD | 99.84% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 94.647% |
| IXICO plc | 1.9 Million USD | 89.417% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 99.02% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.805% |
| CSL Limited | 18.62 Billion USD | 99.999% |
| Cellectis S.A. | 249.36 Million USD | 99.919% |